Clinical studies were performed on the perinatal use of imipenem (IPM)/cilastatin sodium (CS). The obtained results are summarized as follows. 1. IPM/CS was administered to 11 perinatal infection cases which included mainly intrauterine infections and 3 mastitis cases in addition. IPM/CS showed excellent effectiveness against 1, good against 11, and the efficacy rates were 85.7%. 2. No side effects nor abnormal laboratory test values were observed.
